Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary POAI Reports Strong Results From Its AI Cancer Drug Evaluation
MINNEAPOLIS , Jan. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) reported the preliminary results of its Discovery 2021 program today, announcing that its Helomics subsidiary’s evaluation demonstrated their proprietary Artificial Intelligence (AI) program CoRE™ (Computational
View HTML
Toggle Summary Predictive Oncology Adjourns Annual Meeting of Stockholders to December 30, 2021
MINNEAPOLIS , Dec. 27, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that the Company’s Annual Meeting of Stockholders was convened at 3:00 p.m.
View HTML
Toggle Summary Predictive Oncology – Year-end Shareholder Update!
EAGAN, Minn. , Dec. 21, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology , (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, is moving in the right direction. In November 2021 , POAI acquired zPREDICTA, a cutting edge cancer
View HTML
Toggle Summary Pamela Bush, Ph.D., MBA, Joins Predictive Oncology as SVP of Strategic Sales and Business Development
Bush to lead Predictive Oncology’s novel sales effort towards cancer research technologies EAGAN, Minn. , Dec. 07, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology , (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, today
View HTML
Toggle Summary Predictive Oncology Acquires zPREDICTA, Inc.
zPREDICTA has developed a patented tumor-specific 3D cell culture platform that is complementary to Predictive Oncology’s Artificial Intelligence (AI) platform developed by Helomics. zPREDICTA’s uniquely designed 3D culture systems create a tumor microenvironment that is closer to the patient’s
View HTML
Toggle Summary Predictive Oncology Reports Third Quarter Financial Results
EAGAN, Minn. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Results from the third quarter show strong potential for future growth, said Predictive Oncology (Nasdaq: POAI) today, announcing financial results for the quarter ended September 30, 2021 . All three of Predictive Oncology’s reportable segments
View HTML
Toggle Summary Predictive Oncology Launches Website Highlighting AI-Powered Cancer Research Advancements
Predictive Oncology is leveraging AI to streamline drug discovery and development, improve outcomes in clinical testing and forge a new frontier of cancer research MINNEAPOLIS , Oct. 19, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology , an oncology and cancer research company using big data and
View HTML
Toggle Summary Predictive Oncology Inc. Announces Newest Board Member
MINNEAPOLIS , Sept. 15, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is excited to announce that Raymond F. Vennare was elected to the Board of Directors,
View HTML
Toggle Summary Predictive Oncology Announces Results of Charter Amendment Proposal at Special Meeting
MINNEAPOLIS , Aug. 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that on August 17, 2021 , the stockholders approved an amendment to the
View HTML
Toggle Summary Predictive Oncology Reports Financial Results for Quarter Ended June 30, 2021, and Provides Business Update
MINNEAPOLIS , Aug. 11, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results for the quarter ended June 30, 2021 , and provided an
View HTML